Argos gets a $40M China deal for AGS-003

John Carroll

's Lummy HK and the BioPharma Capital I Fund have agreed to acquire $ 10 million worth of Durham, NC-based Therapeutics stock in exchange for rights to develop and commercialize ' AGS-003 personalized cancer drug in China, Hong Kong, Taiwan and Macau.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS